[go: up one dir, main page]

SI1730110T1 - Žveplove spojine kot inhibitorji NS3 serin proteaze virusa hepatitisa C - Google Patents

Žveplove spojine kot inhibitorji NS3 serin proteaze virusa hepatitisa C

Info

Publication number
SI1730110T1
SI1730110T1 SI200531086T SI200531086T SI1730110T1 SI 1730110 T1 SI1730110 T1 SI 1730110T1 SI 200531086 T SI200531086 T SI 200531086T SI 200531086 T SI200531086 T SI 200531086T SI 1730110 T1 SI1730110 T1 SI 1730110T1
Authority
SI
Slovenia
Prior art keywords
hepatitis
virus
inhibitors
serine protease
sulfur compounds
Prior art date
Application number
SI200531086T
Other languages
English (en)
Inventor
Frank Bennett
Raymond G Lovey
Yuhua Huang
Siska Hendrata
Anil K Saksena
Stephane L Bogen
Yi-Tsung Liu
F George Njoroge
Srikanth Venkatraman
Kevin X Chen
Mousumi Sannigrahi
Ashok Arasappan
Viyyoor M Girijavallabhan
Francisco Velazquez
Latha Nair
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of SI1730110T1 publication Critical patent/SI1730110T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200531086T 2004-02-27 2005-02-24 Žveplove spojine kot inhibitorji NS3 serin proteaze virusa hepatitisa C SI1730110T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54867004P 2004-02-27 2004-02-27
EP05723607A EP1730110B9 (en) 2004-02-27 2005-02-24 Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
PCT/US2005/005795 WO2005087731A1 (en) 2004-02-27 2005-02-24 Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease

Publications (1)

Publication Number Publication Date
SI1730110T1 true SI1730110T1 (sl) 2010-10-29

Family

ID=34961556

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531086T SI1730110T1 (sl) 2004-02-27 2005-02-24 Žveplove spojine kot inhibitorji NS3 serin proteaze virusa hepatitisa C

Country Status (31)

Country Link
US (1) US8067379B2 (sl)
EP (1) EP1730110B9 (sl)
JP (1) JP4714732B2 (sl)
KR (2) KR101316137B1 (sl)
CN (2) CN103102389A (sl)
AR (1) AR048241A1 (sl)
AT (1) ATE470660T1 (sl)
AU (1) AU2005222060A1 (sl)
BR (1) BRPI0508085A (sl)
CA (1) CA2557495C (sl)
CY (1) CY1111212T1 (sl)
DE (1) DE602005021760D1 (sl)
DK (1) DK1730110T3 (sl)
EC (1) ECSP066791A (sl)
ES (1) ES2346233T3 (sl)
HK (1) HK1095819A1 (sl)
HR (1) HRP20100416T1 (sl)
IL (1) IL177544A (sl)
MY (1) MY145081A (sl)
NO (1) NO20064358L (sl)
NZ (1) NZ549223A (sl)
PE (1) PE20051150A1 (sl)
PL (1) PL1730110T3 (sl)
PT (1) PT1730110E (sl)
RS (1) RS51394B (sl)
RU (1) RU2428428C9 (sl)
SG (1) SG186041A1 (sl)
SI (1) SI1730110T1 (sl)
TW (2) TWI314927B (sl)
WO (1) WO2005087731A1 (sl)
ZA (1) ZA200607096B (sl)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE212037T1 (de) 1996-10-18 2002-02-15 Vertex Pharma Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
SI1730110T1 (sl) * 2004-02-27 2010-10-29 Schering Corp Žveplove spojine kot inhibitorji NS3 serin proteaze virusa hepatitisa C
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
GB0426661D0 (en) * 2004-12-06 2005-01-05 Isis Innovation Pyrrolidine compounds
WO2006130666A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
NZ563369A (en) * 2005-06-02 2011-03-31 Schering Corp Controlled-release formulation useful for treating disorders associated with hepatitus C virus
WO2006130626A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
WO2006130554A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
JP5160415B2 (ja) * 2005-06-02 2013-03-13 メルク・シャープ・アンド・ドーム・コーポレーション 医薬処方物およびそれを用いる治療方法
US20070021351A1 (en) * 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
PL1891089T3 (pl) 2005-06-02 2015-05-29 Merck Sharp & Dohme Inhibitory proteazy HCV w połączeniu z pokarmem
WO2006130552A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP2009528353A (ja) * 2006-03-03 2009-08-06 シェーリング コーポレイション Ｈｃｖのプロテアーゼ阻害剤およびｉｒｅｓ阻害剤の医薬的組み合わせ
AU2007227580A1 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Processes and intermediates for preparing steric compounds
US20070287664A1 (en) * 2006-03-23 2007-12-13 Schering Corporation Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
NZ571826A (en) 2006-04-11 2012-01-12 Novartis Ag HCV/HIV inhibitors and their uses
DE102006059317A1 (de) 2006-07-04 2008-01-10 Evonik Degussa Gmbh Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden
RU2009109355A (ru) 2006-08-17 2010-09-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Ингибиторы вырусной полимеразы
EP2099430A2 (en) * 2006-12-07 2009-09-16 Schering Corporation Ph sensitive matrix formulation
US8546420B2 (en) 2006-12-22 2013-10-01 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
WO2008078563A1 (ja) * 2006-12-22 2008-07-03 Sumitomo Seika Chemicals Co., Ltd. ３－ベンジルオキシベンゼンチオールの製造方法
KR20090094154A (ko) 2006-12-22 2009-09-03 쉐링 코포레이션 Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
CN101611025A (zh) 2006-12-22 2009-12-23 先灵公司 5,6-环化的吲哚衍生物及其使用方法
JP2010535156A (ja) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
BRPI0816116A2 (pt) 2007-08-29 2015-03-03 Schering Corp Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
WO2009032125A1 (en) 2007-08-29 2009-03-12 Schering Corporation 2,3-substituted azaindole derivatives for treating viral infections
PE20090630A1 (es) 2007-08-29 2009-05-16 Schering Corp Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
DK2061513T3 (da) 2007-09-14 2011-11-21 Schering Corp Fremgangsmåde til behandling af patienter med hepatitis C
EP2205584A1 (en) * 2007-10-10 2010-07-14 Novartis Ag Spiropyrrolidines and their use against hcv and hiv infection
US8765757B2 (en) 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
WO2009064852A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
MX2010006313A (es) 2007-12-19 2010-06-25 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
US7964560B2 (en) * 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2010013630A (es) 2008-06-13 2010-12-21 Schering Corp Derivados triciclicos de indol y metodos de uso de los mismos.
EP2323631A1 (en) * 2008-08-07 2011-05-25 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
EP2376078A2 (en) 2008-12-12 2011-10-19 Schering Corporation Deuterated compounds as hepatitis c virus (hcv) inhibitors
RU2011127080A (ru) 2009-01-07 2013-02-20 Сайнексис, Инк. Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
CA2768838A1 (en) * 2009-07-29 2011-02-03 Schering Corporation Enantio- and stereo-specific syntheses of beta-amino-alpha- hydroxy amides
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
AU2010341537A1 (en) 2009-12-22 2012-08-09 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
AR080676A1 (es) 2010-03-09 2012-05-02 Schering Corp Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
EP2598149A4 (en) 2010-07-26 2014-09-10 Merck Sharp & Dohme SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
US9133116B2 (en) 2010-09-28 2015-09-15 Panacea Biotec Ltd. Bicyclic compounds
EP2621279B1 (en) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012073249A1 (en) 2010-12-01 2012-06-07 Arch Pharmalabs Limited A novel process for the preparation of 3-(benzyloxy)- benzenethiol, a key intermediate for the preparation of pharmaceutical drugs.
JP2014515023A (ja) 2011-04-13 2014-06-26 メルク・シャープ・アンド・ドーム・コーポレーション ２’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
EP3063140A4 (en) 2013-10-30 2017-11-08 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
WO2017059411A1 (en) * 2015-10-01 2017-04-06 Memorial Sloan-Kettering Cancer Center Inhibitors of menaquinone biosynthesis
US10874686B2 (en) 2015-10-01 2020-12-29 Memorial Sloan-Kettering Cancer Center Anthranilyl-adenosinemonosulfamate analogs and uses thereof
AU2017282653B2 (en) 2016-06-21 2021-08-12 Orion Ophthalmology LLC Aliphatic prolinamide derivatives
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
WO2024153137A1 (zh) * 2023-01-17 2024-07-25 西藏海思科制药有限公司 一种手性氨基醇医药中间体的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133402T2 (de) * 1990-04-04 2004-11-11 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Protease von hepatitis-c-virus
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
ATE212037T1 (de) 1996-10-18 2002-02-15 Vertex Pharma Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
AU757072B2 (en) 1997-08-11 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
ATE297946T1 (de) 2000-04-03 2005-07-15 Vertex Pharma Inhibitoren von serin proteasen, speziell der hepatitis-c-virus ns3-protease
RU2002129564A (ru) 2000-04-05 2004-05-10 Шеринг Корпорейшн (US) Макроциклические ингибиторы сериновой ns3-протеазы, включающие n-циклические р2 структурные элементы вируса гепатита с
CA2406532A1 (en) 2000-04-19 2001-11-01 Schering Corporation Macrocyclic ns-3 serine protease inhibitors of hepatitis c virus compri sing alkyl and aryl alanine p2 moieties
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
KR100904788B1 (ko) * 2000-07-21 2009-06-25 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드
SK742003A3 (en) 2000-07-21 2003-06-03 Schering Corp Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
US20020068702A1 (en) 2000-07-21 2002-06-06 Marguerita Lim-Wilby Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1343807B1 (en) 2000-12-12 2009-04-29 Schering Corporation Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
SI1730110T1 (sl) * 2004-02-27 2010-10-29 Schering Corp Žveplove spojine kot inhibitorji NS3 serin proteaze virusa hepatitisa C
US7816326B2 (en) * 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
JP5160415B2 (ja) 2005-06-02 2013-03-13 メルク・シャープ・アンド・ドーム・コーポレーション 医薬処方物およびそれを用いる治療方法

Also Published As

Publication number Publication date
DK1730110T3 (da) 2010-09-27
TWI314927B (en) 2009-09-21
ECSP066791A (es) 2006-11-16
CA2557495A1 (en) 2005-09-22
JP2007525514A (ja) 2007-09-06
ES2346233T3 (es) 2010-10-13
TW200530183A (en) 2005-09-16
SG186041A1 (en) 2012-12-28
US8067379B2 (en) 2011-11-29
IL177544A0 (en) 2006-12-10
ATE470660T1 (de) 2010-06-15
EP1730110B1 (en) 2010-06-09
KR20060134083A (ko) 2006-12-27
AU2005222060A1 (en) 2005-09-22
NZ549223A (en) 2010-10-29
KR101316137B1 (ko) 2013-10-10
EP1730110B9 (en) 2011-11-02
CY1111212T1 (el) 2015-06-11
TW200938526A (en) 2009-09-16
RU2428428C2 (ru) 2011-09-10
HK1095819A1 (en) 2007-07-27
PE20051150A1 (es) 2006-01-16
US20070042968A1 (en) 2007-02-22
PT1730110E (pt) 2010-09-14
AR048241A1 (es) 2006-04-12
MY145081A (en) 2011-12-15
CN101076516A (zh) 2007-11-21
CA2557495C (en) 2014-04-15
BRPI0508085A (pt) 2007-07-17
WO2005087731A1 (en) 2005-09-22
PL1730110T3 (pl) 2010-11-30
DE602005021760D1 (de) 2010-07-22
NO20064358L (no) 2006-11-24
HRP20100416T1 (hr) 2010-09-30
WO2005087731A8 (en) 2006-06-22
JP4714732B2 (ja) 2011-06-29
CN103102389A (zh) 2013-05-15
RU2428428C9 (ru) 2012-03-10
RS51394B (en) 2011-02-28
IL177544A (en) 2015-02-26
EP1730110A1 (en) 2006-12-13
KR20130018418A (ko) 2013-02-21
ZA200607096B (en) 2008-09-25
RU2006134003A (ru) 2008-04-10
TWI393704B (zh) 2013-04-21
AU2009225346A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
HK1095819A1 (en) Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
IL177545A0 (en) Compounds as inhibitors of hepatitis c virus ns3 serine protease
HK1095837A1 (en) Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
HK1099028A1 (en) Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
ZA200907353B (en) Sulfur compounds as inhibitors of Hepatitis C Virus NS3 serine protease
IL177503A0 (en) Inhibitors of hepatitis c virus ns3 protease
HK1095820A1 (en) 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
IL176237A0 (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
IL174459A0 (en) Macrocyclic inhibitors of hepatitis c virus ns3 serine protease
IL177628A0 (en) Novel ketoamides with cyclic p4s as inhibitors of ns3 serine protease of hepatitis c virus
TWI367211B (en) Hcv ns-3 serine protease inhibitors
DE602006009280D1 (de) Inhibitoren der hcv-ns3-protease
IL195512A0 (en) Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
EP2125870A4 (en) INHIBITORS OF HEPATITIS C NS3 PROTEASE
AU2009225346B2 (en) Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease